

# Day 2 May 19 (Thu.) 2022

Plenary Session
Scientific Program
Educational Session
Free Papers(Oral)
Social Event
E English Session
 V Simultaneous Interpretation
 Web Live-Stream Session

|                             |               | 7:00                                | 8:00   | 9:00                         | 10:00   | 11:00              | 12:00   | 13:00   | 14:00                       | 15:00                                 | 16:00                      | 17:00  | 18:00                        | 19:00          | 20:00  | 21:00 |  |
|-----------------------------|---------------|-------------------------------------|--|------------------------------|---|--------------------|---|---|-----------------------------|---------------------------------------|----------------------------|--|------------------------------|----------------|--|-------|--|
| TOKYO INTERNATIONAL FORUM   | Hall Building | Room 1                              | Hall A (4F)  |                              |   |                    | Web PL<br>Plenary Lecture                         |   | Web Pr<br>President Lecture | Web Members Meeting                   | Web Awards Ceremony        | Web AAW<br>Japanese Society of Neurology 2021 Award Winner Lecture   |                              |                |  |       |  |
|                             | Room 2        | Hall C (4F)                         |  |                              |   |                    |   |   |                             | Web SPL-01<br>Semi-Plenary Lecture 01 | Web SLe<br>Special Lecture |  |                              |                |  |       |  |
|                             | Room 3        | Hall B7(1) (7F)                     | Web Symposium 09<br>Clinical and pathological heterogeneity in multiple system atrophy   |                              |   | O-12<br>Dementia 1 |   | Web LS-13<br>Eli Lilly Japan K.K. / DAIICHI SANKYO COMPANY, LIMITED |                             |                                       |                            | Web Symposium 16<br>Frontiers of animal models for neurodegenerative diseases  |                              |                | Web ES-01<br>Medical Affairs, Amgen K.K.       |       |  |
|                             | Room 4        | Hall B7(2) (7F)                     | LM-03<br>Lecture Marathon 03   | LM-04<br>Lecture Marathon 04 | O-13<br>Parkinsonism and Related disorders 3            |                    | LS-15<br>Eisai Co., Ltd.                          |   |                             |                                       |                            | LM-05<br>Lecture Marathon 05   | LM-06<br>Lecture Marathon 06 |                | Web ES-02<br>Boston Scientific Japan K.K.      |       |  |
|                             | Room 5        | Hall B5(1) (5F)                     | Web Symposium 10<br>Personalized medicine for ultra-rare disease by nucleic acid drug  |                              | O-14<br>Motor neuron disease 1                          |                    | Web LS-16<br>Mitsubishi Tanabe Pharma Corporation |   |                             |                                       |                            | Web Symposium 17<br>Integrated understanding of physiology and imaging based on the genetic dystonia                   |                              |                |  |       |  |
|                             | Room 6        | Hall B5(2) (5F)                     | Web Symposium 11<br>Current topics in the diagnosis and pathogenesis of spinal cord disorders  |                              | O-15<br>Muscle diseases 2                               |                    | Web LS-17<br>ONO PHARMACEUTICAL CO.,LTD.          |   |                             |                                       |                            | Web Symposium 18<br>Medical Exam and Rehab for obstinate neurological disease with ICT                                 |                              |                |  |       |  |
|                             | Room 7        | Hall D7 (7F)                        | Web Symposium 12<br>Treatment strategy for recurrent ischemic stroke   |                              | O-16<br>Cerebrovascular disease 3                       |                    | Web LS-18<br>Biogen Japan Ltd. / Eisai Co., Ltd.  |   |                             |                                       |                            | Hot Topics 04<br>Etiological basis of Alzheimer's disease and its implication in disease-modifying therapies           |                              |                | Web ES-03<br>Otsuka Pharmaceutical Co., Ltd.   |       |  |
|                             | Room 8        | Hall D5 (5F)                        | Web Symposium 13<br>Transcranial ultrasound stimulation (TUS) in humans  |                              | O-17<br>Neuroimmunology 2                               |                    | Web LS-19<br>FUJIREBIO INC.                       |   |                             |                                       |                            | 2022 Special Symposium 02<br>Decoding of glial function; To understand the physiology and pathophysiology of the brain |                              |                |  |       |  |
|                             | Room 9        | Hall D1 (1F)                        | Web Symposium 14<br>The current topics on pathophysiology and complications of narcolepsy  |                              | O-18<br>Peripheral neuropathy and Metabolic disorders 1 |                    | Web LS-20<br>Astellas Pharma Inc.                 |   |                             |                                       |                            | International Education Course 01<br>Neuro-ICU and Dedicated Neurocritical Care Team in Neurology                      |                              |                |  |       |  |
|                             | Room 10       | Conference Room G409 (4F)           | Web Hot Topics 03<br>Paradigm shift of migraine management   |                              | O-19<br>Neurorehabilitation                             |                    | Web LS-21<br>Alexion Pharma GK                    |   |                             |                                       |                            | Web Hot Topics 05<br>Cutting edge of stroke genetics: what to know & what to do  |                              |                | Web ES-04<br>Novartis Pharma K.K.              |       |  |
|                             | Room 11       | Conference Room G701 (7F)           | Web Symposium 15<br>Competence of general medical practice of a neurologist: requirement for neurology as a speciality in the Japanese medical speciality system |                              | O-20<br>Neuroimaging                                    |                    | Web LS-22<br>Kyowa Kirin Co.,Ltd.                 |   |                             |                                       |                            | LB<br>Late Breaking Symposium  |                              |                | ES-05<br>Takeda Pharmaceutical Company Limited |       |  |
|                             | Room 12       | Conference Room G402 (4F)           |  |                              | O-21<br>Muscle diseases 3                               |                    | LS-23<br>DAIICHI SANKYO COMPANY, LIMITED          |   |                             |                                       |                            |  |                              |                | Web ES-06<br>Glaxo Smith Kline K.K.            |       |  |
|                             | Room 13       | Conference Room G502 (5F)           |  |                              | O-22<br>Pediatric neurology                             |                    | Web LS-24<br>Sanofi K.K.                          |   |                             |                                       |                            |  |                              |                | Web ES-07<br>Eli Lilly Japan K.K.              |       |  |
|                             | Room 14       | Conference Room G510 (5F)           |  |                              | O-23<br>Epilepsy  |                    | Web LS-25<br>Pfizer Japan Inc.                    |   |                             |                                       |                            |  |                              |                |  |       |  |
|                             | Room 15       | Conference Room G602 (6F)           |  |                              | O-24<br>Clinical Neurophysiology 1                      |                    | LS-26<br>FP Pharmaceutical Corporation            |   |                             |                                       |                            | 2022 Special Symposium 03<br>Advanced science for next-generation nucleic acid medicine                                |                              |                |  |       |  |
| Poster Session / Exhibition | Hall E (B2F)  | Poster Preparation / Poster Viewing |  |                              |   |                    | Poster Viewing                                    |   |                             |                                       |                            | Poster Presentation / Discussion   |                              | Poster Removal |  |       |  |

DAY 2